Specialty
Aesthetics Cataract & Refractive Dermatology General Ophthalmology Glaucoma Interventional Radiology Neurology Optometry Retina Women's Health View All Courses
Course Type
Supplement Multimedia Webinar In-Person Multi-Part Collection
Search
Log In

From Trials to Treatments – Part 2

By: David S. Boyer, MD; Charles C. Wykoff, MD, PhD

This course has expired. You can still review the content but course credit is no longer available.

Webinar Credits: 1

Retinal disorders, including age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO) can result in vision loss if not treated early and—in some disorders—continuously. Significant challenges lie ahead in addressing these patients’ needs, as healthcare providers are being tasked with treating increasing numbers of patients. Prevent Blindness America has found the total healthcare costs of vision problems in the U.S. in people older than 40 years to reach almost $139 billion annually.

It is clear that retina specialists will continue to see an increasing number of patients in the future, as both society ages and as more people develop sight-threatening retina diseases. The need to be fully educated on the various treatment options remains crucial to delivering the best patient care. This need should be expanded beyond exposure to multiple clinical trial data and into “real world” outcomes. Increasing awareness about the more sophisticated imaging devices that are being used in clinics to confirm retina disease diagnoses and newer surgical devices, coupled with the increased interest in developing pharmacologic treatments with longer duration of action or novel mechanisms of action, will be necessary for retina physicians to continue to deliver superior patient care.

Expiration Date: Wednesday, October 31, 2018
Release Date: October 17, 2017

Learning Objectives

Upon completion of this activity, the participant should be able to:

  • Recognize the importance of early diagnosis and treatment of age-related macular degeneration and diabetic macular edema
  • Assess the response of anti-vascular endothelial growth factor intravitreal injections, and define “suboptimal responders”
  • Understand the most recent monotherapy and combination therapy clinical study evidence using available therapies for AMD, DME, and RVO
  • Discuss the outcomes of pivotal studies in AMD, DME, and RVO and how study results may differ from “real-world” dosing methods
  • Develop individualized treatment plans for patients with retina disorders that use a combination of imaging, treat and extend, or treat and observe
  • Discuss the ocular and systemic effects of anti-VEGF therapies and how to educate patients on appropriate expectations

Accreditation and Designation Statement

Accreditation Statement
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
Evolve Medical Education LLC designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Faculty and Disclosures

The following faculty members have the following financial relationships with commercial interests:

David S. Boyer, MD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Allegan; Allegro; Alcon Laboratories, Inc; Aerpio; Bausch & Lomb; Bayer; Genentech, Inc; Roche; Regeneron Pharmaceuticals, Inc.; Clearside Biomedical; Santen; Apellis; OHR; Ora; and Thrombogenics.

Charles C. Wykoff, MD, PhD, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/ Speaker’s Bureau: Alcon; Alimera Sciences, Inc.; Alnylam; Apellis Pharmaceutical; Bayer Pharmaceuticals; Clearside Biomedical, Inc.; DORC International; Genentech, Inc.; ONL Therapeutics; Regeneron Pharmaceuticals, Inc; Roche; ThromboGenics NV; Tyrogenex; and Valeant. Grant/Research Support: Acucela Inc; Alcon; Allegro Ophthalmics; Allergan, Inc.; Ampio Pharmaceuticals Inc.; Apellis Pharmaceuticals Clearside Biomedical, Inc.; Genentech, Inc; Iconic Therapeutics; Opthotech Corporation; pSivida; Regeneron Pharmaceuticals, Inc; Santen Pharmaceutical Co., Ltd.; ThromboGenics NV; and XOMA Corporation.

Editorial Support Disclosure

Michelle Dalton, Writer and Cheryl Cavanaugh, MS, Evolve Medical Education LLC have no real or apparent conflicts of interest to report.

Rishi P. Singh, MD, Peer Reviewer,  has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau:  Alcon; Allergan  Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.

Video Resources

BackNext